Views & Reviews
No Holds Barred
Margaret McCartney: The “breakthrough” drug that’s not been shown to help in Alzheimer’s disease
BMJ 2015; 351 doi: http://dx.doi.org/10.1136/bmj.h4064 (Published 24 July 2015)
Cite this as: BMJ 2015;351:h4064
Rapid responses

Re: Margaret McCartney: The “breakthrough” drug that’s not been shown to help in Alzheimer’s disease
Combination of Monocloinal Antibodies,
β-Secretase inhibitor and a Anti-Tau agent with or without a Cholinesterase inhibitors for Alzheimer 's Disease .
In Alzheimer 's disease amyloid accumulation likely starts many years before the onset of symptoms. There are many pathways involved in amyloid synthesis and deposition cascade in the
Pathogenesis of Alzheimer ' s disease. so using of modified versions of monoclonal antibodies such as Solanezumab may not give a successful outcome. So along with monoclonal antibodies a combination of an another drug that decreases deposits of amyloid, for example, a β-secretase inhibitor, which targets an earlier step on the amyloid pathway, might have superior results. Addition of one more drug that target tau might also provide much more benefit along with above combination.
So a combination of Monocloinal antibodies, a β-secretase inhibitor and a anti-tau agent with or without a Cholinesterase inhibitors is ideal treatment strategy for prevention and progression of Alzhemier' s disease .
As far as Solanezumab is concern it may be well tolerated and without evidence of meningoencephalitis, microhemorrage or vasogenic edema. It can produce physiological changes in the amount of amyloid beta concentrations in the plasma and CSF, but Solanezumab in recent study shows no evidence of cognitive or functional improvement in patients with Alzheimer’s disease
Competing interests: No competing interests
01 August 2015
M A Aleem
Neurologist
ABC Hospital
Annamalainagar Trichy 620015 Tamilnadu India
No comments:
Post a Comment